Immitis (Rivastigmine Hydrogen Tartrate)

Rivastigmine hydrogen tartrate reversibly inhibits both acetylcholinesterase and butyrylcholinesterase enzymes in the central nervous system. By blocking these enzymes, it slows the breakdown of acetylcholine, increasing its concentration at synaptic clefts. The enhanced cholinergic neurotransmission helps to compensate for the loss of cholinergic neurons that occurs in Alzheimer’s disease and Parkinson’s disease dementia, thereby improving cognitive function.

The specific dose of Immitis is determined by the prescribing clinician based on the patient’s clinical status, tolerability, and response to therapy. Typically, treatment is initiated at a low dose and titrated upward at regular intervals, but the exact regimen, including tablet strength and frequency, must be individualized and documented in the prescription. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for rivastigmine hydrogen tartrate in pregnancy and lactation are limited. The drug is generally classified as contraindicated or used only when the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and alternatives with their healthcare provider before initiating therapy.

To request Immitis, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation. The sales team will then respond with pricing, availability, shipping details—including any temperature‑controlled logistics if needed—and assistance with import documentation.

Immitis (rivastigmine) belongs to the cholinesterase inhibitor class, similar to donepezil and galantamine. Compared with these agents, rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, which may offer broader cholinergic enhancement. Its oral formulation is often used when patients experience inadequate response or intolerance to other inhibitors, though it may be associated with a higher incidence of gastrointestinal side effects. Choice of therapy depends on individual patient factors, tolerability, and clinician judgment.

Immitis should be stored at ambient temperature, preferably below 25 °C (77 °F). Keep the product in its original packaging to protect it from moisture, light, and excessive heat. Do not store in bathrooms or near kitchen appliances. If the product is a tablet, ensure the container remains tightly closed. Dispose of any unused medication according to local regulations or return it to a pharmacy for proper disposal.

Immitis is taken orally, usually with food to lessen gastrointestinal discomfort. The tablet should be swallowed whole with a full glass of water and not chewed, crushed, or split unless specifically instructed by a healthcare professional. Dosing schedules are typically once or twice daily, depending on the prescribed regimen. Patients should adhere to the timing recommended by their prescriber and maintain consistent administration times to achieve stable drug levels.

The most serious risks of Immitis include severe bradycardia, which can lead to fainting or heart block, and gastrointestinal bleeding, especially in patients taking anticoagulants or NSAIDs. Hepatic dysfunction may also occur, requiring monitoring of liver enzymes. Rare but severe reactions such as cholinergic crisis, seizures, or serious skin reactions (e.g., Stevens‑Johnson syndrome) demand immediate medical attention. Patients should be educated to report any concerning symptoms promptly.

Immitis is contraindicated in patients with known hypersensitivity to rivastigmine or any of its excipients. It should be avoided in individuals with severe hepatic impairment, active peptic ulcer disease, or uncontrolled asthma, as cholinergic stimulation may exacerbate these conditions. Patients taking other cholinesterase inhibitors or high‑dose anticholinergic medications should not use Immitis without specialist guidance. Pregnant or breastfeeding women should only use the drug when clearly indicated and after thorough risk‑benefit assessment by their clinician.